title: Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
abstract: This study explores amino acid changes of the reverse transcriptase (rt) of CRF01_AE isolates from pregnant women naive to antiretroviral drugs before and 2, 6, and 52 weeks after exposure to single dose nevirapine (sdNVP). Results based on 51 observations showed that the proportion of isolates with nonnucleoside reverse transcriptase inhibitor (NNRTI) RMs in the group treated with sdNVP (n = 35) increased from 0% pre-NVP to 22.9% at week 2 postpartum (pp) and 22.9% at week 6 pp. In the group treated with zidovudine + sdNVP (n = 16), the proportion with RM was 31.3% and 18.8% at weeks 2 and 6 pp, respectively. Only a few RMs were still detected at week 52 pp. No apparent subtype-specific treatment-related mutations were detected. NNRTI RM occurrence in CRF01_AE strains is similar to subtype A, D, and CRF02_AG strains after exposure to antiretroviral drugs for PMTCT.
authors.affiliation: Institut Pasteur du Cambodge, Phnom Penh, Cambodia. naryly@pasteur-kh.org
authors.forename: Nary
authors.initials: N
authors.lastname: Ly
authors.forename: Viseth
authors.initials: V
authors.lastname: Phoung
authors.forename: Duong Chan
authors.initials: DC
authors.lastname: Min
authors.forename: Chanthan
authors.initials: C
authors.lastname: Srey
authors.forename: Leang Sim
authors.initials: LS
authors.lastname: Kruy
authors.forename: Kanal
authors.initials: K
authors.lastname: Koum
authors.forename: Vannarith
authors.initials: V
authors.lastname: Chhum
authors.forename: Philippe
authors.initials: P
authors.lastname: Glaziou
authors.forename: Hervé J
authors.initials: HJ
authors.lastname: Fleury
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Reynes
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002160:Cambodia; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008969:Molecular Sequence Data; D009154:Mutation; D019829:Nevirapine / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019829:Nevirapine; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase